Vor to Develop Multi-Targeted CAR-Ts with Abound Bio

CAMBRIDGE, Mass. and PITTSBURGH, June 10, 2021 (GLOBE NEWSWIRE) — Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a multi-year strategic collaboration and license agreement to research both single- and multi-targeted CAR-T treatments to be used in combination with Vor’s engineered hematopoietic stem cell (eHSC) platform, with the goal of generating novel treatment systems for patients fighting acute myeloid leukemia (AML) and other devastating forms of blood cancer.

Click here to view original post